CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,165,474
- in 11 filings, $3.7M under 10b5-1 plans
Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-28 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −2,283 | $4.63 | $11K | 263,190 |
| 2025-01-28 | Catinazzo Thomas Chief Financial Officer | Grant or award 10b5-1 | +139,141 | 402,331 | ||
| 2025-01-28 | Bergstrom Donald A President, R&D | Sale | −3,220 | $4.63 | $15K | 516,868 |
| 2025-01-28 | Bergstrom Donald A President, R&D | Grant or award | +176,400 | 693,268 | ||
| 2025-01-28 | Adams Brian Chief Legal Officer | Sale | −33,688 | $4.63 | $156K | 287,920 |
| 2025-01-28 | Adams Brian Chief Legal Officer | Grant or award | +139,141 | 427,061 | ||
| 2025-01-23 | Patel Sanjiv President and CEO | Sale 10b5-1 | −125,000 | $4.78 | $598K | 199,548 |
| 2025-01-22 | Patel Sanjiv President and CEO | Sale 10b5-1 | −125,000 | $4.80 | $600K | 324,548 |
| 2025-01-21 | Patel Sanjiv President and CEO | Sale 10b5-1 | −125,000 | $4.52 | $565K | 449,548 |
| 2025-01-10 | Rahmer Peter See remarks | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-01-10 | Adams Brian Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-01-10 | Patel Sanjiv President and CEO | Grant or award · Stock Option (Right to Buy) | +1,105,000 | 1,105,000 | ||
| 2025-01-10 | Bergstrom Donald A President, R&D | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-01-10 | Catinazzo Thomas Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-01-06 | Rahmer Peter See remarks | Sale 10b5-1 | −16,576 | $4.45 | $74K | 308,754 |
| 2025-01-03 | Rahmer Peter See remarks | Sale 10b5-1 | −32,177 | $4.30 | $138K | 325,330 |
| 2025-01-02 | Rahmer Peter See remarks | Sale 10b5-1 | −32,156 | $4.15 | $133K | 357,507 |
| 2024-12-27 | Adams Brian Chief Legal Officer | Sale | −299 | $4.38 | $1K | 321,608 |
| 2024-12-27 | Bergstrom Donald A President, R&D | Sale | −657 | $4.38 | $3K | 520,088 |
| 2024-12-27 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −299 | $4.38 | $1K | 303,792 |
Page 7 of 17 · 329 trades